Larimar Therapeutics: Wedbush cuts target price to $9 from $11
LRMR•Wedbush cut its target price for Larimar Therapeutics to $9 from $11.
Related News

Scotiabank: Raymond James raises target price to C$142.5 from C$139
BNS•

KIDZ AI teams up with Synestria to explore AI infrastructure optimization
KIDZ•

BTQ’s QPerfect receives first funding payment for EU quantum chip project
BTQ•

Energizer productivity, cost cuts drive fiscal Q4 2026 adjusted EBITDA growth of 13%
ENR•

Dollar Tree initiates coverage with buy rating; price target $160
DLTR•